Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Kala Bio, Inc. KALA

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-27.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 11-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -27.0
-50M-100M
20152018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2022 · Operating -2099.3% · Net -1151.6%
-10000%-20000%-30000%
201520202025
ROE
FY2025 · ROE -279.2%
-100%-200%-300%
201520202025
Three returns, three denominators.

Each USD of equity lost 279 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2019 · FCF -94.1
-40M-80M
201520202025

Total assetsUSD 9.5M
EquityUSD 7.0M
CashUSD 7.6M
Current ratio3.81×

Equity funds 74% of total assets.

The 11-year record

11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
KALA, 11-year financial record
Metric 20252024202320222021202020192018201720162015
Revenue $B0.00.00.00.00.00.00.0◌0.00.00.0
Operating income $B−0.0−0.0−0.0−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.00.00.0◌
Net income $B−0.0−0.0−0.0−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0
Free cash flow $B◌◌◌◌◌◌−0.1−0.1−0.0−0.0−0.0
EPS, diluted $−3.31−10.15−17.35−29.48−108.32−1.99−2.76−2.49−3.71−28.07−14.89
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————
ROE %−279.2−388.3−318.7−250.6−244.2−160.9−140.1−68.6———
Shares out B0.030.010.000.000.070.060.040.030.020.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 42 reconciliationsAUDITED

Reconciled in 11 of the 11 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. Eight checks were skipped: EPS is not tagged before 2015.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2015

Share this section

Download image